aspirin has been researched along with Myeloproliferative Disorders in 66 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "In myeloproliferative neoplasms (MPNs), the immature platelet fraction (IPF) rises due to enhanced platelet turnover, and this has been thought to reduce the efficacy of aspirin." | 5.91 | Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter? ( Akay, OM; Erdoğan Özünal, I; Göktürk, A; Kaya, AH; Koçak Göktürk, I; Öztürk, E; Yılmaz, G, 2023) |
| "Retroperitoneal hematoma is a rare complication of psoas catheter placement, typically occurring several days after placement and in the setting of anticoagulation." | 5.43 | Acute Retroperitoneal Hematoma After Psoas Catheter Placement in a Patient with Myeloproliferative Thrombocytosis and Aspirin Therapy. ( Duncan, CM; Kopp, SL; Warner, NS, 2016) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| "Twenty-seven patients with chronic myeloproliferative disorders and in vitro evidence of platelet hyperactivity on whole blood platelet lumi-aggregometry were commenced on anti-platelet therapy comprising aspirin, clopidogrel, and/or odorless garlic and the studies were repeated to assess the efficacy of the therapeutic agent(s)." | 3.73 | Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. ( Gemmell, R; Hartwell, T; Manoharan, A, 2006) |
| " The abnormalities were increased during episodes of clinical thrombosis and could be suppressed in two-thirds of cases by aspirin therapy." | 3.66 | Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. ( Allington, MJ; Boughton, BJ; King, A, 1978) |
| "Risk factors for hemorrhage are less well defined than those for thrombosis." | 2.80 | Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. ( Gao, J; Kander, EM; McMahon, BJ; Raza, S; Stein, BL; Zakarija, A; Zhou, Z, 2015) |
| "Myeloproliferative neoplasms (MPNs) are increasingly being identified in women of childbearing potential." | 2.61 | Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis. ( Fazelzad, R; Gupta, V; Kazi, S; Malinowski, AK; Maze, D; Shah, PS; Shehata, N, 2019) |
| "Age and history of thrombosis are the criteria used to stratify patients to the most appropriate therapeutic options." | 2.46 | JAK2 mutation and thrombosis in the myeloproliferative neoplasms. ( Vannucchi, AM, 2010) |
| "Placental infarction due to thrombosis seems to be the most consistent event." | 2.40 | Fertility, pregnancy and the management of myeloproliferative disorders. ( Bergmann, L; Griesshammer, M; Pearson, T, 1998) |
| "Bleeding and thrombosis are major causes of morbidity and mortality in patients with myeloproliferative disorders." | 2.37 | Bleeding and thrombosis in the myeloproliferative disorders. ( Schafer, AI, 1984) |
| "In myeloproliferative neoplasms (MPNs), the immature platelet fraction (IPF) rises due to enhanced platelet turnover, and this has been thought to reduce the efficacy of aspirin." | 1.91 | Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter? ( Akay, OM; Erdoğan Özünal, I; Göktürk, A; Kaya, AH; Koçak Göktürk, I; Öztürk, E; Yılmaz, G, 2023) |
| "Aspirin resistance was assessed using whole blood MEA (Multiplate®, Roche Diagnostics, Meylan, France)." | 1.48 | Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. ( Galinat, H; Ianotto, JC; Lippert, E; Mingant, F; Perrier-Cornet, A; Perrot, M, 2018) |
| "Retroperitoneal hematoma is a rare complication of psoas catheter placement, typically occurring several days after placement and in the setting of anticoagulation." | 1.43 | Acute Retroperitoneal Hematoma After Psoas Catheter Placement in a Patient with Myeloproliferative Thrombocytosis and Aspirin Therapy. ( Duncan, CM; Kopp, SL; Warner, NS, 2016) |
| "The myeloproliferative disorders have been the "poor cousins" in the family of hematological malignancies for some time." | 1.33 | Platelets and thrombosis in myeloproliferative diseases. ( Harrison, CN, 2005) |
| "Bleeding and thrombosis are well known major causes of morbidity and mortality in patients with myeloproliferative disorders (MPD) but the relationship between these clinical events and the commonly found platelet function abnormalities have not been established." | 1.27 | Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. ( Baker, RI; Manoharan, A, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (33.33) | 18.7374 |
| 1990's | 12 (18.18) | 18.2507 |
| 2000's | 8 (12.12) | 29.6817 |
| 2010's | 17 (25.76) | 24.3611 |
| 2020's | 7 (10.61) | 2.80 |
| Authors | Studies |
|---|---|
| Goulart, H | 1 |
| Mascarenhas, J | 2 |
| Tremblay, D | 1 |
| Edahiro, Y | 1 |
| Koçak Göktürk, I | 1 |
| Erdoğan Özünal, I | 1 |
| Göktürk, A | 1 |
| Kaya, AH | 1 |
| Yılmaz, G | 1 |
| Akay, OM | 1 |
| Öztürk, E | 1 |
| Lucijanic, M | 1 |
| Skelin, M | 1 |
| Kusec, R | 1 |
| Maze, D | 1 |
| Kazi, S | 1 |
| Gupta, V | 1 |
| Malinowski, AK | 1 |
| Fazelzad, R | 1 |
| Shah, PS | 1 |
| Shehata, N | 1 |
| Barbui, T | 8 |
| Ghirardi, A | 1 |
| Vannucchi, AM | 2 |
| Marchetti, M | 2 |
| De Stefano, V | 2 |
| Lucchesi, A | 1 |
| Carloni, S | 1 |
| De Matteis, S | 1 |
| Ghetti, M | 1 |
| Musuraca, G | 1 |
| Poggiaspalla, M | 1 |
| Augello, AF | 1 |
| Giordano, G | 1 |
| Fattori, PP | 1 |
| Martinelli, G | 1 |
| Napolitano, R | 1 |
| Xie, J | 1 |
| Geng, L | 1 |
| Yuan, B | 1 |
| Guo, Y | 1 |
| Zhang, Z | 1 |
| Gangat, N | 1 |
| Tefferi, A | 1 |
| Liyanapthirana, C | 1 |
| Neal, R | 1 |
| Iordanov, T | 1 |
| Nahhas, A | 1 |
| Usui, N | 1 |
| Perrier-Cornet, A | 1 |
| Ianotto, JC | 2 |
| Mingant, F | 2 |
| Perrot, M | 1 |
| Lippert, E | 2 |
| Galinat, H | 2 |
| Finazzi, G | 3 |
| Stolyar, MA | 1 |
| Ivashin, DS | 1 |
| Olkhovsky, IA | 1 |
| Lew, J | 1 |
| Frucht, SJ | 1 |
| Kremyanskaya, M | 1 |
| Hoffman, R | 1 |
| Lavi, N | 1 |
| Brenner, B | 1 |
| Avivi, I | 1 |
| Robier, C | 2 |
| Stettin, M | 2 |
| Neubauer, M | 2 |
| Quehenberger, F | 1 |
| Neumeister, P | 1 |
| Alvarez-Larrán, A | 1 |
| Besses, C | 1 |
| Kander, EM | 1 |
| Raza, S | 1 |
| Zhou, Z | 1 |
| Gao, J | 1 |
| Zakarija, A | 1 |
| McMahon, BJ | 1 |
| Stein, BL | 1 |
| Warner, NS | 1 |
| Duncan, CM | 1 |
| Kopp, SL | 1 |
| Gillet, B | 1 |
| Didier, R | 1 |
| Gilard, M | 1 |
| Ugo, V | 1 |
| Bain, BJ | 1 |
| Baud, P | 1 |
| Tobler, A | 1 |
| Lämmle, B | 1 |
| Alberio, L | 1 |
| Spivak, JL | 1 |
| Barosi, G | 1 |
| Tognoni, G | 1 |
| Marchioli, R | 2 |
| Harrison, CN | 1 |
| Landolfi, R | 2 |
| Di Gennaro, L | 1 |
| Novarese, L | 1 |
| Patrono, C | 1 |
| Eikelboom, J | 1 |
| Manoharan, A | 2 |
| Gemmell, R | 1 |
| Hartwell, T | 1 |
| Viero, P | 3 |
| Cortelazzo, S | 3 |
| Bassan, R | 1 |
| Ireland, H | 1 |
| Lane, DA | 1 |
| Wolff, S | 1 |
| Foadi, M | 1 |
| de Gaetano, G | 3 |
| Schafer, AI | 1 |
| Boughton, BJ | 2 |
| Jerrome, DW | 1 |
| Rychetnik, M | 1 |
| Meschengieser, SS | 1 |
| Woods, AI | 1 |
| Schattner, MA | 1 |
| Lazzari, MA | 1 |
| Phadke, K | 1 |
| Dean, S | 1 |
| Pitney, WR | 1 |
| Sidorova, LD | 1 |
| Arkhipov, BF | 1 |
| Degtiareva, MM | 1 |
| Barkagan, LZ | 1 |
| Salem, HH | 1 |
| van der Weyden, MB | 1 |
| Koutts, J | 1 |
| Firkin, BG | 1 |
| Mughal, TI | 1 |
| Matsumoto, H | 1 |
| Michiels, JJ | 5 |
| van Genderen, PJ | 3 |
| Jansen, PH | 1 |
| Koudstaal, PJ | 1 |
| Leenknegt, H | 1 |
| Budde, U | 1 |
| Dapling, RB | 1 |
| Snowden, JA | 1 |
| West, J | 1 |
| Talbot, JF | 1 |
| Nelson, ME | 1 |
| Greaves, M | 1 |
| Griesshammer, M | 3 |
| Bangerter, M | 1 |
| van Vliet, HH | 1 |
| Wehmeier, A | 2 |
| Südhoff, T | 1 |
| Meierkord, F | 1 |
| Kutti, J | 1 |
| Stark, P | 1 |
| Bazzan, M | 1 |
| Gugliotta, L | 1 |
| Brière, J | 2 |
| Kiladjian, JJ | 1 |
| Berlin, NI | 1 |
| Pearson, TC | 1 |
| Green, AC | 1 |
| Fruchtmann, SM | 1 |
| Silver, RT | 1 |
| Hansmann, E | 1 |
| Lengfelder, E | 1 |
| Kvasnicka, HM | 1 |
| Hasselbalch, H | 1 |
| Cervantes, F | 1 |
| Thiele, J | 1 |
| Bergmann, L | 1 |
| Pearson, T | 1 |
| Allington, MJ | 1 |
| King, A | 1 |
| Okuma, M | 2 |
| Uchino, H | 1 |
| Boss, GR | 1 |
| Seegmiller, JE | 1 |
| Gordon, DH | 1 |
| Schaffner, D | 1 |
| Bennett, JM | 1 |
| Schwartz, SI | 1 |
| Zieve, PD | 1 |
| Levin, J | 1 |
| Levesque, H | 1 |
| Cailleux, N | 1 |
| Courtois, H | 1 |
| Goldstein, R | 1 |
| Clark, P | 1 |
| Klintmalm, G | 1 |
| Husberg, B | 1 |
| Gonwa, T | 1 |
| Stone, M | 1 |
| Luzzatto, G | 1 |
| Fabris, F | 1 |
| Mazzucato, M | 1 |
| Girolami, A | 1 |
| Niikura, H | 1 |
| Baker, RI | 1 |
| Buelli, M | 1 |
| Weiss, HJ | 1 |
| Neemeh, JA | 1 |
| Bowie, EJ | 1 |
| Thompson, JH | 1 |
| Didisheim, P | 1 |
| Owen, CA | 1 |
23 reviews available for aspirin and Myeloproliferative Disorders
| Article | Year |
|---|---|
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quality of | 2022 |
Treatment options and pregnancy management for patients with PV and ET.
Topics: Aspirin; Female; Humans; Hydroxyurea; Janus Kinase 2; Janus Kinase Inhibitors; Myeloproliferative Di | 2022 |
Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.
Topics: Antineoplastic Agents; Aspirin; Birth Rate; Female; Fibrinolytic Agents; Heparin; Humans; Interferon | 2019 |
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.
Topics: Abortion, Habitual; Abortion, Spontaneous; Anticoagulants; Aspirin; Combined Modality Therapy; Femal | 2021 |
Antiplatelet therapy in the management of myeloproliferative neoplasms.
Topics: Aspirin; Disease Management; Female; Humans; Male; Myeloproliferative Disorders; Platelet Aggregatio | 2014 |
JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Ag | 2010 |
Chronic myeloproliferative disorders.
Topics: Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Hematopoietic Stem Cell Tr | 2003 |
Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Platelet Activation; Polycythemia Vera; Thrombocythem | 2006 |
Aspirin resistance: does it exist and is it an important clinical problem?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidog | 2006 |
Platelets, prostaglandins and thrombotic disorders.
Topics: Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Coronary Disease; Cyclic AMP | 1981 |
Bleeding and thrombosis in the myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acids; Aspirin; Blood Viscosity; Epinephrine; Hematocrit; Hemorrhage; | 1984 |
Primary thrombocythemia: a current perspective.
Topics: Aspirin; Diagnosis, Differential; Humans; Hydroxyurea; Interferon Type I; Myeloproliferative Disorde | 1995 |
[Erythromelalgia--review of clinical characteristics and therapy].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Erythromelalgia; F | 1993 |
Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.
Topics: Adult; Aged; Aspirin; Capillaries; Cerebral Arteries; Diagnosis, Differential; Erythromelalgia; Fema | 1996 |
Acquired von Willebrand disease in myeloproliferative disorders.
Topics: Aspirin; Autoantibodies; Bleeding Time; Contraindications; Humans; Myeloproliferative Disorders; Pla | 1996 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acid; Aspirin; Bleeding Time; Blood Platelets; Bone Marrow; Hematopoi | 1997 |
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Topics: Aspirin; Bone Marrow; Bone Marrow Transplantation; Diagnosis, Differential; Follow-Up Studies; Granu | 1999 |
Fertility, pregnancy and the management of myeloproliferative disorders.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Alkylating Agents; Animals; Aspirin; Bone Marrow | 1998 |
Hyperuricemia and gout. Classification, complications and management.
Topics: Acute Disease; Allopurinol; Arthritis; Aspirin; Colchicine; Coronary Disease; Diuretics; Gout; Human | 1979 |
Qualitative disorders of platelets.
Topics: Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Humans; Myeloproliferative Disorders | 1976 |
[Thrombosis in various diseases: myeloproliferative disorders].
Topics: Aspirin; beta-Thromboglobulin; Blood Coagulation Factors; Busulfan; Carbazilquinone; Dipyridamole; H | 1986 |
Bleeding disorders due to abnormal platelet function.
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Fa | 1973 |
2 trials available for aspirin and Myeloproliferative Disorders
| Article | Year |
|---|---|
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Female; Fusion Proteins, bcr-abl; | 2015 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
41 other studies available for aspirin and Myeloproliferative Disorders
| Article | Year |
|---|---|
Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?
Topics: Aspirin; Blood Platelets; Humans; Hydroxyurea; Myeloproliferative Disorders; Neoplasms | 2023 |
Second primary malignancies in myeloproliferative neoplasms and the role of aspirin.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Neoplasms, Second Primary; Platelet Aggregation | 2019 |
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Neoplasms, Second Primary; Platelet Aggregation | 2020 |
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Chronic Disease; Fibrinogen; Humans; Middl | 2020 |
Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Topics: Adult; Aspirin; Blood Platelets; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Mutation; M | 2020 |
A rare consequence of very common osteoporotic pubic rami fracture in a patient with myeloproliferative disease.
Topics: Accidental Falls; Aged, 80 and over; Aspirin; Blood Transfusion; Female; Fractures, Bone; Hematoma; | 2017 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematop | 2017 |
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Drug Resistance; F | 2018 |
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myeloproliferative Disorders; Recurre | 2018 |
[ON THE ISSUE OF SELECTION OF COAGULANTS UNDER ADP-INDUCED IMPEDANCE TEST OF AGGREGATION OF THROMBOCYTES IN PATIENTS WITH CHRONIC MYELO-PROLIFERATIVE TUMORS].
Topics: Adenosine Triphosphate; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Citrates; Electric Im | 2017 |
Hemichorea in a patient with JAK2V617F blood cells.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Aspirin; Chorea; Female; Humans; Hydroxyurea; Janu | 2013 |
Management of pregnant women with myeloproliferative neoplasms.
Topics: Adult; Aspirin; Blood Viscosity; Female; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Inc | 2013 |
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies | 2013 |
Assessment of the response to acetylsalicylic acid in patients with myeloproliferative neoplasms by whole blood assays: a comparison of the PFA-100 with multiple electrode aggregometry.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biological Assay; Blood Platelets; Female; Humans; Male; Mi | 2014 |
Acute Retroperitoneal Hematoma After Psoas Catheter Placement in a Patient with Myeloproliferative Thrombocytosis and Aspirin Therapy.
Topics: Aged, 80 and over; Aspirin; Catheters; Gastrointestinal Hemorrhage; Hematoma; Humans; Male; Myelopro | 2016 |
Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance.
Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Drug Resistance; Electro | 2016 |
How to manage children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antiviral Agents; | 2012 |
Bone marrow biopsy morbidity and mortality.
Topics: Anticoagulants; Aspirin; Biopsy, Needle; Bone Marrow Examination; Hemorrhage; Humans; Myeloprolifera | 2003 |
Acquired von Willebrand syndrome in a myeloproliferative disorder. Case 6.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Male; Middle Aged; Myeloproliferative Diso | 2003 |
Platelets and thrombosis in myeloproliferative diseases.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Endothelium, Vascular; Hematocrit; Humans; Janus | 2005 |
Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders.
Topics: Aspirin; Chronic Disease; Clopidogrel; Dietary Supplements; Dose-Response Relationship, Drug; Garlic | 2006 |
Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Female; Humans; Leukemi | 1982 |
In vivo platelet release in myeloproliferative disorders.
Topics: Aged; Aspirin; beta-Thromboglobulin; Blood Platelets; Fibrinopeptide A; Fibrinopeptide B; Humans; Mi | 1982 |
Chronic myeloproliferative disorders: a quantitative assessment of platelet ultrastructure.
Topics: Aspirin; Blood Platelets; Chronic Disease; Cytoplasmic Granules; Humans; Myeloproliferative Disorder | 1980 |
[Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Topics: Adult; Aspirin; Blood Platelet Disorders; Dipyridamole; Female; Humans; Leukemia, Myeloid; Male; Mid | 1981 |
Platelet dysfunction in myeloproliferative syndromes.
Topics: Aspirin; Blood Platelets; Humans; Malondialdehyde; Mathematics; Myeloproliferative Disorders; Platel | 1981 |
[Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
Topics: Aged; Aspirin; Chronic Disease; Hemorrhagic Disorders; Humans; Male; Myeloproliferative Disorders; P | 1981 |
Leg pain and platelet aggregates in thrombocythemic myeloproliferative disease.
Topics: Aged; Aspirin; Female; Foot; Humans; Ischemia; Male; Microcirculation; Middle Aged; Myeloproliferati | 1980 |
The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography.
Topics: Adult; Aged; Aged, 80 and over; Allergens; Antineoplastic Agents; Arterial Occlusive Diseases; Aspir | 1996 |
Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders.
Topics: Aspirin; Bone Marrow Examination; Clinical Trials as Topic; Clone Cells; Congresses as Topic; Diseas | 2001 |
Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis.
Topics: Aspirin; Beta-Globulins; Blood Platelets; Female; Humans; Male; Myeloproliferative Disorders; Thromb | 1978 |
Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders.
Topics: Adult; Aged; Arachidonic Acids; Aspirin; Blood Platelets; Female; Humans; Lipoxygenase; Male; Middle | 1979 |
Postsplenectomy thrombocytosis: its association with mesenteric, portal, and/or renal vein thrombosis in patients with myeloproliferative disorders.
Topics: Aged; Aspirin; Female; Heparin; Humans; Male; Middle Aged; Myeloproliferative Disorders; Preoperativ | 1978 |
[Erythromelalgia in adults. Apropos of 16 cases].
Topics: Adult; Aspirin; Erythromelalgia; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders | 1992 |
Prevention of recurrent thrombosis following liver transplantation for Budd-Chiari syndrome associated with myeloproliferative disorders: treatment with hydroxyurea and aspirin.
Topics: Adult; Aspirin; Budd-Chiari Syndrome; Female; Humans; Hydroxyurea; Liver Transplantation; Male; Myel | 1991 |
PF 4 versus beta TG as evidence for platelet activation in myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Dipyridamole; Female; Human | 1985 |
Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time.
Topics: Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Female; Follow-Up Studies; Hemorrhage; Hum | 1988 |
Aspirin and risk of bleeding in patients with thrombocythemia.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Adolescent; Adult; Aged; Aspirin; Bleeding Time; Blood P | 1987 |
Defective platelet aggregation induced by platelet activating factor in myeloproliferative disorders: deficiency of an aspirin-independent mechanism?
Topics: Adult; Aged; Aspirin; Drug Synergism; Epinephrine; Female; Humans; In Vitro Techniques; Male; Middle | 1986 |
[Arachidonic acids].
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Diabetes Mellitus; Humans; Methods; Myeloproliferative | 1985 |
Quantitation of platelet aggregation in myeloproliferative disorders.
Topics: Absorption; Adenosine Diphosphate; Aspirin; Collagen; Densitometry; Epinephrine; Humans; Light; Meth | 1972 |